FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 127 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR A ‘sponge on a string’ test to detect oesophageal cancer earlier July 31, 2020 That Cancer Conversation is back! April 19, 2023 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Cómo mantenerse seguro e independiente durante el tratamiento contra el cáncer July 1, 2021 Load more HOT NEWS FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated... Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker Steps towards a smokefree society
